Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04043143 · ClinicalTrials.gov registry record · NA

24-hour Oral Morphine Equivalent Based Opioid Prescribing After Surgery

A NA study, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
57
Enrollment target

NCT04043143: Completed NA study, sponsored by University of Colorado, Denver.

NCT04043143 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04043143, a NA study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target

Study Summary

The investigators will utilize the electronic health record to individualize pain therapy in surgical patients after hospital discharge using last 24-hour opioid intake as the decision variable for the amount of opioid pain pills prescribed. The preliminary data indicate that current opioid prescription practice after surgery follows a "one size fits all" pattern. In-hospital opioid use 24 hours prior to discharge serves as a strong indicator to correctly estimate needs for analgesic medications at home. The investigators will test the hypothesis that this prescription estimation tool will enable providers to write need-based prescriptions based on each patient's' 24-hour prior-to-discharge opioid use. The investigators will test this tool prospectively for patients after Cesarean section who are anticipated to use about half or less of the usually prescribed amount of opioid pain pills after discharge randomized equally to prescription tool intervention or no intervention (prescription as usual).

Primary Outcome

Prescribed post-discharge opioid doses in oral morphine equivalents from the electronic health record (EHR).

Interventions

  • OTHER Arm 1 Prescription As Usual
  • OTHER Arm 2 Prescription Tool Intervention

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2019-10-24
Est. Completion 2021-01-13
Phase NA
University of Colorado, Denver

1,283 total trials

What the finished NCT04043143 record still lists

NCT04043143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Arm 1 Prescription As Usual is the first listed.

NCT04043143 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04043143 about?

NCT04043143 is a clinical study titled "24-hour Oral Morphine Equivalent Based Opioid Prescribing After Surgery". The investigators will utilize the electronic health record to individualize pain therapy in surgical patients after hospital discharge using last 24-hour opioid intake as the decision variable for the amount of opioid pain pills prescribed. The preliminary data indicate that current opioid prescrip...

What is the current status of trial NCT04043143?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2019-10-24. Estimated completion is 2021-01-13.

What interventions are being tested in trial NCT04043143?

The interventions under investigation include: Arm 1 Prescription As Usual (OTHER), Arm 2 Prescription Tool Intervention (OTHER).

Who is sponsoring clinical trial NCT04043143?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04043143's enrollment target sits among peer trials

57 1261st of 2000 higher than 739 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04043143, the US trial registry maintained by the National Library of Medicine. NCT04043143 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.